Cas:143-10-2 1-Decanethiol manufacturer & supplier

We serve Chemical Name:1-Decanethiol CAS:143-10-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-Decanethiol

Chemical Name:1-Decanethiol
CAS.NO:143-10-2
Synonyms:n-decyl mercaptan;2-F-octylethanethiol;decanethiolnormal;EINECS 205-584-2;decylthiol;Acetic acid, 2-hydrazinyl-;Decan-1-thiol;decanethiol;Hydrazinoacetic acid;1-MERCAPTODECANE;MERCAPTAN C10;Decyl Mercaptan;MFCD00004884;n-decylmercaptane;decane-1-thiol;decylmercaptane
Molecular Formula:C10H22S
Molecular Weight:90.081
HS Code:2930909090

Physical and Chemical Properties:
Melting point:−26 °C(lit.)
Boiling point:366.8±25.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.495
PSA:38.80000
Exact Mass:90.042931
LogP:-1.41

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3334
Packing Group:II; III


Contact us for information like n-decyl mercaptan chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,decylmercaptane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,n-decylmercaptane Use and application,Decyl Mercaptan technical grade,usp/ep/jp grade.


Related News: The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. 1-Decanethiol manufacturer Ultimately there’s likely a broad mix of social, cultural and economic drivers at play, suggested Lona Sandon, program director of the Department of Clinical Nutrition in the School of Health Professions at the UT Southwestern Medical Center in Dallas. She was not part of the research. 1-Decanethiol supplier The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. 1-Decanethiol vendor It wasn’t known if this was due to racial differences in breast cancer-related genetic mutations, making it unclear whether race should help guide genetic testing. 1-Decanethiol factory The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years.